Folate-conjugated boron nitride nanospheres for targeted delivery of anticancer drugs.
With its unique physical and chemical properties and structural similarity to carbon, boron nitride (BN) has attracted considerable attention and found many applications. Biomedical applications of BN have recently started to emerge, raising great hopes in drug and gene delivery. Here, we developed a targeted anticancer drug delivery system based on folate-conjugated BN nanospheres (BNNS) with receptor-mediated targeting. Folic acid (FA) was successfully grafted onto BNNS via esterification reaction. In vitro cytotoxicity assay showed that BNNS-FA complexes were non-toxic to HeLa cells up to a concentration of 100 μg/mL. Then, doxorubicin hydrochloride (DOX), a commonly used anticancer drug, was loaded onto BNNS-FA complexes. BNNS-FA/DOX complexes were stable at pH 7.4 but effectively released DOX at pH 5.0, which exhibited a pH sensitive and sustained release pattern. BNNS-FA/DOX complexes could be recognized and specifically internalized by HeLa cells via FA receptor-mediated endocytosis. BNNS-FA/DOX complexes exhibited greater cytotoxicity to HeLa cells than free DOX and BNNS/DOX complexes due to the increased cellular uptake of DOX mediated by the FA receptor. Therefore, BNNS-FA complexes had strong potential for targeted cancer therapy.
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Republic of China.
Shini
S
Feng
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Republic of China.
Huijie
H
Zhang
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Republic of China.
Ting
T
Yan
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Republic of China.
Dandi
D
Huang
Department of Physics and Materials Science, City University of Hong Kong, Hong Kong SAR, People's Republic of China.
Chunyi
C
Zhi
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Republic of China.
Hideki
H
Nakanishi
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, People's Republic of China.
Xiao-Dong
XD
Gao
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D001896:Boron Compounds / Q000737:chemistry*; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D004705:Endocytosis / Q000187:drug effects; D005492:Folic Acid / Q000008:administration & dosage / Q000737:chemistry; D006367:HeLa Cells / Q000187:drug effects; D006801:Humans; D054118:Nanospheres / Q000008:administration & dosage* / Q000737:chemistry*; D017550:Spectroscopy, Fourier Transform Infrared
D000970:Antineoplastic Agents; D001896:Boron Compounds; D004337:Drug Carriers; C017282:boron nitride; D004317:Doxorubicin; D005492:Folic Acid
boron nitride nanospheres; cancer therapy; doxorubicin; folic acid; targeted delivery
Nanomedicine (Lond). 2015 Jul;10(12):1911-22
25835434
Acc Chem Res. 2011 Oct 18;44(10):1114-22
21732606
Chem Commun (Camb). 2013 Aug 25;49(66):7337-9
23851619
Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):3-23
21237228
Nat Nanotechnol. 2007 Dec;2(12):751-60
18654426
Int J Nanomedicine. 2013;8:1783-93
23674892
ACS Appl Mater Interfaces. 2015 Aug 12;7(31):17217-25
26192448
J Am Chem Soc. 2009 Jan 28;131(3):890-1
19119844
Anal Biochem. 2005 Mar 15;338(2):284-93
15745749
Biochemistry. 1994 Nov 22;33(46):13761-8
7947787
Langmuir. 2013 Sep 24;29(38):12003-12
23971901
Small. 2013 May 27;9(9-10):1672-85
23423826
ACS Nano. 2014 Jun 24;8(6):6123-30
24797563
Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51
12204596
Int J Nanomedicine. 2012;7:19-24
22275819
Biotechnol Bioeng. 2008 Nov 1;101(4):850-8
18512259
Chem Commun (Camb). 2008 Jan 28;(4):459-61
18188467
Acc Chem Res. 2011 Oct 18;44(10 ):936-46
21612199
Angew Chem Int Ed Engl. 2009;48(41):7668-72
19760685
Int J Pharm. 2015 Mar 15;481(1-2):56-63
25637832
Nanoscale Res Lett. 2008 Nov 25;4(2):113-121
20596476
Nanoscale. 2012 Oct 21;4(20):6343-50
22941279
Biomaterials. 2013 Apr;34(12):3087-97
23374705
Nat Mater. 2013 Nov;12(11):991-1003
24150417
J Am Chem Soc. 2011 Nov 9;133(44):17560-3
21985458
Bioorg Med Chem. 2005 Sep 1;13(17):5043-54
15955702
J Control Release. 2010 Jan 25;141(2):252-9
19778560
ACS Nano. 2009 Jan 27;3(1):197-206
19206267
Science. 1995 Aug 18;269(5226):966-7
17807732
J Appl Toxicol. 1998 May-Jun;18(3):215-23
9685051
Int J Nanomedicine. 2015 Aug 24;10:5343-53
26346655
Nanoscale Res Lett. 2010 May 09;5(7):1093-101
20596329
ACS Nano. 2010 Jun 22;4(6):2979-93
20462272
ACS Nano. 2011 May 24;5(5):3800-10
21495683
Med Res Rev. 1999 Nov;19(6):477-96
10557366
Chem Commun (Camb). 2014 Apr 28;50(33):4371-4
24643626
Drug Discov Today. 2001 Jan 1;6(1):44-51
11165172
Int J Pharm. 2013 Feb 28;444(1-2):85-8
23357257
Colloids Surf B Biointerfaces. 2012 Jan 1;89:1-9
21982868